These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 33021110)

  • 1. Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism.
    Panza F; Lozupone M; Watling M; Imbimbo BP
    Expert Opin Pharmacother; 2021 Feb; 22(3):325-337. PubMed ID: 33021110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Management of Dementia with Lewy Bodies.
    Hershey LA; Coleman-Jackson R
    Drugs Aging; 2019 Apr; 36(4):309-319. PubMed ID: 30680679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update.
    MacDonald S; Shah AS; Tousi B
    Drugs Aging; 2022 Jul; 39(7):505-522. PubMed ID: 35619045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data.
    Tousi B; Leverenz JB
    Drug Des Devel Ther; 2021; 15():1811-1817. PubMed ID: 33976533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study.
    Murata M; Odawara T; Hasegawa K; Iiyama S; Nakamura M; Tagawa M; Kosaka K
    Neurology; 2018 Feb; 90(8):e664-e672. PubMed ID: 29367449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study.
    Ikeda M; Mori E; Orimo S; Yamada T; Konishi O
    J Alzheimers Dis; 2023; 95(1):251-264. PubMed ID: 37483001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial.
    Murata M; Odawara T; Hasegawa K; Kajiwara R; Takeuchi H; Tagawa M; Kosaka K
    Parkinsonism Relat Disord; 2020 Jul; 76():91-97. PubMed ID: 31982288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical drug development for dementia with Lewy bodies: past and present.
    Lee G; Cummings J; Decourt B; Leverenz JB; Sabbagh MN
    Expert Opin Investig Drugs; 2019 Nov; 28(11):951-965. PubMed ID: 31614096
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials.
    Hasegawa K; Kochi K; Maruyama H; Konishi O; Toya S; Odawara T
    J Alzheimers Dis; 2021; 79(2):627-637. PubMed ID: 33337365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review.
    Kong L; Xi J; Jiang Z; Yu X; Liu H; Wang Z
    Biomed Res Int; 2022; 2022():4817488. PubMed ID: 36132085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
    Jellinger KA
    J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the pharmacotherapeutic management of dementia with Lewy bodies.
    Palermo G; Ceravolo R; Bonuccelli U
    Expert Opin Pharmacother; 2018 Oct; 19(15):1643-1653. PubMed ID: 30212224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
    Jellinger KA; Korczyn AD
    BMC Med; 2018 Mar; 16(1):34. PubMed ID: 29510692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic trials in dementia with Lewy bodies: a systematic review of the literature].
    Sacrez M; Lamothe M; Rauch L; Botzung A; Blanc F
    Geriatr Psychol Neuropsychiatr Vieil; 2021 Sep; 19(3):289-304. PubMed ID: 34609295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial.
    Odawara T; Hasegawa K; Kajiwara R; Takeuchi H; Tagawa M; Kosaka K; Murata M
    Am J Geriatr Psychiatry; 2022 Mar; 30(3):314-328. PubMed ID: 34420834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging drugs for dementia with Lewy Bodies: a review of Phase II & III trials.
    Tolea MI; Ezzeddine R; Camacho S; Galvin JE
    Expert Opin Emerg Drugs; 2023 Dec; 28(3):167-180. PubMed ID: 37531299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia--common features and differences].
    Drach LM
    Med Monatsschr Pharm; 2011 Feb; 34(2):47-52; quiz 53-4. PubMed ID: 21428015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials.
    Tsuboi Y; Kochi K; Maruyama H; Matsumoto Y
    eNeurologicalSci; 2022 Mar; 26():100384. PubMed ID: 34988303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dementia with Lewy bodies: emerging drug targets and therapeutics.
    Pope ED; Cordes L; Shi J; Mari Z; Decourt B; Sabbagh MN
    Expert Opin Investig Drugs; 2021 Jun; 30(6):603-609. PubMed ID: 33899637
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.